AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BioLineRx Ltd.

Proxy Solicitation & Information Statement Jun 24, 2023

6692_rns_2023-06-23_1860cef6-0f1d-4319-bd6f-b31d4fdf53ea.pdf

Proxy Solicitation & Information Statement

Open in Viewer

Opens in native device viewer

BIOLINERX LTD.

For the Annual General Meeting of Shareholders to be held on August 7, 2023

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned shareholder of BioLineRx Ltd. (the "Company") hereby appoints Mali Zeevi and/or Raziel Fried, and each or either of them, the true and lawful attorney, agent and proxy of the undersigned, with full power of substitution, to vote, as designated below, all of the ordinary shares of the Company which the undersigned is entitled in any capacity to vote at the Annual General Meeting of the shareholders of the Company which will be held at the offices of the Company at Modi'in Technology Park, 2 HaMa'ayan Street, Modi'in 7177871, Israel, on August 7, 2023 at 3:00 p.m. (Israel time), and all adjournments and postponements thereof.

(CONTINUED AND TO BE SIGNED ON REVERSE SIDE)

SEE REVERSE SIDE

ANNUAL GENERAL MEETING OF SHAREHOLDERS OF

BIOLINERX LTD.

August 7, 2023

THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED HEREIN. IF NO DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED "FOR" THE ELECTION OF THE DIRECTORS NAMED IN ITEM 1 AND "FOR" ALL OTHER PROPOSALS.

VOTES CAST FOR ITEM 2 WILL NOT BE COUNTED UNLESS "YES" OR "NO" HAS BEEN SPECIFIED AS TO WHETHER THE SHAREHOLDER HAS A PERSONAL INTEREST (AS DEFINED IN THE PROXY STATEMENT) WITH RESPECT TO SUCH PROPOSAL

Please mark your vote for the following resolutions as in this example

1. TO APPROVE the re-election of the following
persons to the Board of Directors, each to serve
until
the
next
annual
general
meeting
of
shareholders and until their respective successors
are duly elected and qualified, or each to serve for
staggered terms ending at the 2024, 2025 and 2026
annual
general
meetings
of
shareholders,
if
Proposal 3 is approved:
FOR AGAINST ABSTAIN
Aharon Schwartz
Michael Anghel
B.J. Bormann
Raphael Hofstein
Sandra Panem
2. TO APPROVE the grant of equity compensation
to Philip Serlin, the Company's Chief Executive
FOR AGAINST ABSTAIN
Officer, as described in Proposal 2 of the Proxy
Statement.
Do you have a "Personal Interest" (as defined in
the Proxy Statement) with respect to the subject
YES NO
matter of Proposal 2? (Please note: if you do not
mark either "YES" or "NO" your shares will
not be voted on Proposal 2)
3. TO
APPROVE
certain
amendments
to
the
Company's Articles of Association relating to the
appointment
of
directors
of
the
Company,
including to classify the Board of Directors (other
than the external directors) into three classes with
staggered
three-year
terms,
as
set
forth
on
Appendix A to the Proxy Statement.
FOR
AGAINST
ABSTAIN
4. TO APPROVE the reappointment of Kesselman &
Kesselman, Certified Public Accountants (Isr.), a
member
firm
of
PricewaterhouseCoopers
International
Limited,
as
the
Company's
independent registered public accounting firm for
the year ending December 31, 2023 and for such
additional period until the next annual general
meeting, and to authorize the Audit Committee of
the Board of Directors to fix the compensation of
said auditors in accordance with the scope and
nature of their services.
FOR
AGAINST
ABSTAIN
Name:
Number of shares:
Signature:
Date:
NOTE: Please mark date and sign exactly as the
name(s) appear on this proxy. If the signer is a
corporation, please sign the full corporate name by
a
duly
authorized
officer.
Executors,
administrators, trustees, etc. should state their full
title or capacity. Joint owners should each sign.

Talk to a Data Expert

Have a question? We'll get back to you promptly.